The disease area stronghold leader in neurodegeneration at Johnson & Johnson discussed data presented at AAIC 2024 highlighting different subtypes of Alzheimer disease that may lead to more personalized treatments. [WATCH TIME: 4 minutes]
Fiona Elwood, PhD
Advertisement
Articles by Fiona Elwood, PhD
The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]
Advertisement
Latest Updated Articles
Utilizing Global Proteomics and Biomarker Research to Advance Alzheimer Precision Medicine: Fiona Elwood, PhDPublished: September 12th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
2
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
3
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
4
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD
5
